Imperial College London
Portrait Picture

ProfessorPaoloMuraro

Faculty of Medicine, Department of Brain Sciences

Professor of Neurology - Neuroimmunology and Immunotherapy
 
 
 
//

Contact

 

p.muraro Website

 
 
//

Assistant

 

Mrs Gearoidin Beazley +44 (0)20 7594 7047

 
//

Location

 

E415Burlington DanesHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Uccelli:2019:10.1186/s13063-019-3346-z,
author = {Uccelli, A and Laroni, A and Brundin, L and Clanet, M and Fernandez, O and Nabavi, SM and Muraro, PA and Oliveri, RS and Radue, EW and Sellner, J and Sorensen, PS and Sormani, MP and Wuerfel, JT and Battaglia, MA and Freedman, MS},
doi = {10.1186/s13063-019-3346-z},
journal = {Trials},
pages = {1--13},
title = {MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis},
url = {http://dx.doi.org/10.1186/s13063-019-3346-z},
volume = {20},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BackgroundMultiple sclerosis (MS) is an inflammatory disease of the central nervous system with a degenerative component, leading to irreversible disability. Mesenchymal stem cells (MSC) have been shown to prevent inflammation and neurodegeneration in animal models of MS, but no large phase II clinical trials have yet assessed the exploratory efficacy of MSC for MS.Methods/designThis is an academic, investigator-initiated, randomized, double-blind, placebo-compared phase I/II clinical trial with autologous, bone-marrow derived MSC in MS. Enrolled subjects will receive autologous MSC at either baseline or at week 24, through a cross-over design. Primary co-objectives are to test safety and efficacy of MSC treatment compared to placebo at 6 months. Secondary objectives will evaluate the efficacy of MSC at clinical and MRI levels. In order to overcome funding constraints, the MEsenchymal StEm cells for Multiple Sclerosis (MESEMS) study has been designed to merge partially independent clinical trials, following harmonized protocols and sharing some key centralized procedures, including data collection and analyses.DiscussionResults will provide patients and the scientific community with data on the safety and efficacy of MSC for MS. The innovative approach utilized to obtain funds to support the MESEMS trial could represent a new model to circumvent limitation of funds encountered by academic trials.
AU  - Uccelli,A
AU  - Laroni,A
AU  - Brundin,L
AU  - Clanet,M
AU  - Fernandez,O
AU  - Nabavi,SM
AU  - Muraro,PA
AU  - Oliveri,RS
AU  - Radue,EW
AU  - Sellner,J
AU  - Sorensen,PS
AU  - Sormani,MP
AU  - Wuerfel,JT
AU  - Battaglia,MA
AU  - Freedman,MS
DO  - 10.1186/s13063-019-3346-z
EP  - 13
PY  - 2019///
SN  - 1745-6215
SP  - 1
TI  - MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis
T2  - Trials
UR  - http://dx.doi.org/10.1186/s13063-019-3346-z
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000467610800001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-019-3346-z
UR  - http://hdl.handle.net/10044/1/72082
VL  - 20
ER  -
Download